Free prostate specific antigen measurement kit and preparation method therefor
AssigneeBeijing Strong Biotechnologies, Inc.
InventorsXiaorui Zhang, Jingjing Zhang, Huaya Cai, Xi Liu
Life of this patent
Estimating the term…
Abstract
A free prostate specific antigen measurement kit and a preparation method therefor. The kit comprises a first reagent and a second reagent, and optionally further comprises a quality control material and/or a calibration material. The first reagent comprises a surfactant and a buffer solution, and the second reagent comprises nanoparticles coated with an antibody and a buffer solution. The kit uses a free prostate specific antigen in a sample to react with an antibody in the second reagent.
Claims20
A detection kit for free prostate-specific antigen, comprising:
- a first reagent,
- a second reagent;
- and
- optionally, a quality control and/or calibrator;
- wherein,
- the first reagent comprises:
- a surfactant, and
- a buffer;
- the second reagent comprises:
- a first nano-microsphere coated with a first antibody,
- a second nano-microsphere coated with a second antibody, and
- a buffer;
- the calibrator comprises human fPSA with known concentration;
- the quality control comprises human fPSA with known concentration;
- the first antibody is an anti-human fPSA antibody;
- the second antibody is an anti-complex antibody, and the second antibody does not bind to human fPSA, but binds to the complex formed by the first antibody and human fPSA;
- the buffer in the first reagent and in the second reagent is independently selected from the group consisting of:
- phosphate buffer, glycine buffer, HEPES buffer, IVIES buffer, boric acid buffer, acetate buffer, ammonium chloride buffer and the combination thereof;
- the concentration of the buffer in the first reagent and in the second reagent is independently 10 mM to 500 mM;
- the pH value of the buffer in the first reagent and in the second reagent is independently 6 to 8.
A method for preparation of a nano-microsphere, comprising the steps of:
- a first step, including:
- 1.1) activating the first nano-microsphere to obtain an activated nano-microsphere;
- 1.2) coupling the first antibody onto the activated nano-microsphere to obtain the first antibody-nano-microsphere conjugate;
- 1.3) blocking the first antibody-nano-microsphere conjugate resulting from step 1.2), a second step, including:
- 2.1) optionally, cross-linking the second antibody and the spacer arm molecule to obtain a complex of the second antibody and the spacer arm molecule;
- 2.2) coupling the second antibody or the complex resulting from step 2.1) onto the second nano-microsphere to obtain the second antibody-nano-microsphere conjugate;
- 2.3) blocking the second antibody-nano-microsphere conjugate resulting from step 2.2),
- a third step:
- mixing the first antibody-nano-microsphere conjugate with the second antibody-nano-microsphere conjugate,
- wherein the first step and second step are performed in parallel or interchangeable;
- the first antibody is an anti-human fPSA antibody;
- the second antibody is an anti-complex antibody, and the second antibody does not bind to human fPSA, but binds to the complex formed by the first antibody and human fPSA.
Dependencies are inferred from the claim text.